Dynavax Technologies Corp DVAX
We take great care to ensure that the data presented and summarized in this overview for DYNAVAX TECHNOLOGIES CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DVAX
View all-
Black Rock Inc. New York, NY21.9MShares$302 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT17.8MShares$245 Million10.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$126 Million0.0% of portfolio
-
State Street Corp Boston, MA7.79MShares$107 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.56MShares$90.5 Million5.31% of portfolio
-
Chicago Capital, LLC5.38MShares$74.2 Million1.84% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.19MShares$71.6 Million1.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.07MShares$56.1 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.49MShares$48.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.99MShares$41.3 Million0.0% of portfolio
Latest Institutional Activity in DVAX
Top Purchases
Top Sells
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Insider Transactions at DVAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
John L Slebir SVP General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,358
-12.84%
|
$64,296
$12.93 P/Share
|
|
Feb 18
2025
|
John L Slebir SVP General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+28.54%
|
-
|
|
Feb 18
2025
|
Robert Janssen SVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,041
-4.96%
|
$48,492
$12.93 P/Share
|
|
Feb 18
2025
|
Robert Janssen SVP and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+12.74%
|
-
|
|
Feb 18
2025
|
Kelly Mac Donald SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,975
-14.55%
|
$59,700
$12.93 P/Share
|
|
Feb 18
2025
|
Kelly Mac Donald SVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,477
+31.15%
|
-
|
|
Feb 18
2025
|
Ryan Spencer CEO and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
36,528
-12.29%
|
$438,336
$12.93 P/Share
|
|
Feb 18
2025
|
Ryan Spencer CEO and Director |
BUY
Exercise of conversion of derivative security
|
Direct |
55,000
+15.61%
|
-
|
|
Feb 18
2025
|
David F Novack President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,665
-16.28%
|
$127,980
$12.93 P/Share
|
|
Feb 18
2025
|
David F Novack President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,620
+25.66%
|
-
|
|
Feb 13
2025
|
Ryan Spencer CEO and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
31,694
-11.57%
|
$380,328
$12.69 P/Share
|
|
Feb 13
2025
|
Ryan Spencer CEO and Director |
BUY
Exercise of conversion of derivative security
|
Direct |
62,500
+18.6%
|
-
|
|
Feb 13
2025
|
Kelly Mac Donald SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,318
-22.12%
|
$63,816
$12.69 P/Share
|
|
Feb 13
2025
|
Kelly Mac Donald SVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+39.96%
|
-
|
|
Feb 13
2025
|
David F Novack President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,480
-22.53%
|
$149,760
$12.69 P/Share
|
|
Feb 13
2025
|
David F Novack President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,500
+32.86%
|
-
|
|
Feb 13
2025
|
John L Slebir SVP General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,708
-15.81%
|
$56,496
$12.69 P/Share
|
|
Feb 13
2025
|
John L Slebir SVP General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+33.02%
|
-
|
|
Feb 13
2025
|
Robert Janssen SVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,614
-6.22%
|
$55,368
$12.69 P/Share
|
|
Feb 13
2025
|
Robert Janssen SVP and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+14.9%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 312K shares |
|---|---|
| Grant, award, or other acquisition | 42.9K shares |
| Payment of exercise price or tax liability | 148K shares |
|---|---|
| Open market or private sale | 3.62K shares |